[HTML][HTML] IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B

J Publicover, A Goodsell, S Nishimura… - The Journal of …, 2011 - Am Soc Clin Investig
J Publicover, A Goodsell, S Nishimura, S Vilarinho, Z Wang, L Avanesyan, R Spolski…
The Journal of clinical investigation, 2011Am Soc Clin Investig
HBV is a noncytopathic hepadnavirus and major human pathogen that causes immune-
mediated acute and chronic hepatitis. The immune response to HBV antigens is age
dependent: viral clearance occurs in most adults, while neonates and children usually
develop chronic infection and liver disease. Here, we characterize an animal model for HBV
infection that recapitulates the key differences in viral clearance between early life and
adulthood and find that IL-21 may be part of an effective primary hepatic immune response …
HBV is a noncytopathic hepadnavirus and major human pathogen that causes immune-mediated acute and chronic hepatitis. The immune response to HBV antigens is age dependent: viral clearance occurs in most adults, while neonates and children usually develop chronic infection and liver disease. Here, we characterize an animal model for HBV infection that recapitulates the key differences in viral clearance between early life and adulthood and find that IL-21 may be part of an effective primary hepatic immune response to HBV. In our model, adult mice showed higher HBV-dependent IL-21 production in liver, compared with that of young mice. Conversely, absence of the IL-21 receptor in adult mice resulted in antigen persistence akin to that of young mice. In humans, levels of IL-21 transcripts were greatly increased in blood samples from acutely infected adults who clear the virus. These observations suggest a different model for the dichotomous, age-dependent outcome of HBV infection in humans, in which decreased IL-21 production in younger patients may hinder generation of crucial CD8+ T and B cell responses. These findings carry implications for therapeutic augmentation of immune responses to HBV and potentially other persistent liver viruses.
The Journal of Clinical Investigation